("SourceBio", the "Company" or the "Group")
Notice of Final Results
Analyst and Investor Briefing
SourceBio International plc (AIM: SBI.L), the international provider of integrated state-of-the-art laboratory services and products, announces that it will release its full year results for the year ended 31 December 2020 on Tuesday 13 April 2021.
Analyst briefing
A briefing open to analysts will take place remotely via video conference call on Tuesday 13 April 2021 at 1:30pm BST and those wishing to participate should contact sourcebio@walbrookpr.com for further details.
Investor briefing
Jay LeCoque, Executive Chairman, Tony Ratcliffe, Chief Financial Officer, and Russell Wheatcroft, Chief Operating Officer, will also provide a live presentation relating to the Final Results via the Investor Meet Company platform on Tuesday 13 April 2021 at 3:00pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet SourceBio International plc via:
https://www.investormeetcompany.com/sourcebio-international-plc/register-investor
Investors who already follow SourceBio International plc on the Investor Meet Company platform will automatically be invited.
Contacts:
| SourceBio International plc | ||
| Jay LeCoque, Executive Chairman | Via Walbrook PR | |
| Tony Ratcliffe, Chief Financial Officer | | |
| | | |
| Liberum (Nominated Adviser and Broker) | Tel: 020 3100 2000 | |
| Bidhi Bhoma | | |
| Euan Brown | | |
| William Hall | | |
| | | |
| Walbrook PR Limited | Tel: 020 7933 8780 or sourcebio@walbrookpr.com | |
| Paul McManus / Sam Allen | Mob: 07980 541 893 / 07748 651 727 | |
About SourceBio International plc www.sourcebiointernational.com
SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four core businesses areas:
· Infectious Disease Testing - a range of COVID-19 testing services for the Department of Health and Social Care (DHSC), the NHS, Private Healthcare groups and Commercial enterprises. Utilising various technologies (RT-qPCR, LamPore and LAMP) SourceBio offers both screening and gold standard COVID-19 testing and operates under the ISO: 15189 accreditation required by the DHSC for COVID-19 test services. SourceBio offers employee testing solutions to industry, home testing kits (including 'Fit to Fly' and 'Test to Release' approved tests) and operates Mobile Testing Unit laboratories to support event and venue testing.
· Healthcare Diagnostics - histopathology and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland.
· Genomics - DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America.
· Stability Storage - shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA.
More details on Group operations can be found here: www.sourcebioscience.com
SourceBio International plc (SBI.L) is listed on the AIM market of the London Stock Exchange.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
